Fred Saad
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Oncology top 0.02%
- Bone health and treatments
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
Papers in
-
- Prostate Cancer Treatment and Research 378
- Prostate Cancer Diagnosis and Treatment 221
- Renal cell carcinoma treatment 94
- Oncology 165
- Bone health and treatments 117
- PARP inhibition in cancer therapy 23
- Co-authors
- Karim S. Fizazi (108 shared papers)Neal D. Shore (85 shared papers)Pierre I. Karakiewicz (251 shared papers)Johann Sebastian De Bono (41 shared papers)Cora Nanette Sternberg (49 shared papers)Kim N. Chi (38 shared papers)Allan Lipton (28 shared papers)Paul N. Mainwaring (14 shared papers)
- Journals
- Annals of Oncology (82 papers)The Journal of Urology (69 papers)European Urology (64 papers)Urologic Oncology Seminars and Original Investigations (62 papers)Clinical Genitourinary Cancer (50 papers)
- Partner nations
- CanadaUnited StatesGermany
In The Last Decade
Fred Saad
1.2k papers receiving 85.9k citations
Fred Saad's Hit Papers
Peers
Comparison fields: 5 of 145
- Pulmonary and Respiratory Medicine 33.7k
- Oncology 13.0k
- Cancer Research 4.9k
- Molecular Biology 5.9k
- Geriatrics and Gerontology 273
Countries citing papers authored by Fred Saad
This map shows the geographic impact of Fred Saad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Saad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Saad more than expected).
Fields of papers citing papers by Fred Saad
This network shows the impact of papers produced by Fred Saad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Saad. The network helps show where Fred Saad may publish in the future.
Co-authors
The 25 scholars most cited alongside Fred Saad, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.3k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The Immune Landscape of Cancer Hit paper breakdown → | 2018 | 4385 |
| 2 | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Hit paper breakdown → | 2012 | 3736 |
| 3 | Abiraterone and Increased Survival in Metastatic Prostate Cancer Hit paper breakdown → | 2011 | 3648 |
| 4 | An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics Hit paper breakdown → | 2018 | 2633 |
| 5 | The Molecular Taxonomy of Primary Prostate Cancer Hit paper breakdown → | 2015 | 2464 |
| 6 | Enzalutamide in Metastatic Prostate Cancer before Chemotherapy Hit paper breakdown → | 2014 | 2460 |
| 7 | Oncogenic Signaling Pathways in The Cancer Genome Atlas Hit paper breakdown → | 2018 | 2371 |
| 8 | Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy Hit paper breakdown → | 2012 | 2313 |
| 9 | Olaparib for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2020 | 1776 |
| 10 | Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer Hit paper breakdown → | 2018 | 1758 |
| 11 | Comprehensive Characterization of Cancer Driver Genes and Mutations Hit paper breakdown → | 2018 | 1748 |
| 12 | Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation Hit paper breakdown → | 2018 | 1634 |
| 13 | A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma Hit paper breakdown → | 2002 | 1335 |
| 14 | Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Hit paper breakdown → | 2012 | 1148 |
| 15 | Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Hit paper breakdown → | 2015 | 1113 |
| 16 | Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer Hit paper breakdown → | 2018 | 1036 |
| 17 | Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer Hit paper breakdown → | 2004 | 961 |
| 18 | Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer Hit paper breakdown → | 2009 | 888 |
| 19 | Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas Hit paper breakdown → | 2018 | 824 |
| 20 | Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer Hit paper breakdown → | 2018 | 808 |
About Fred Saad
Fred Saad is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Urology, having authored 1.3k papers that have together received 87.7k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (378 papers), Prostate Cancer Diagnosis and Treatment (221 papers), Bladder and Urothelial Cancer Treatments (150 papers), Bone health and treatments (117 papers), Renal cell carcinoma treatment (94 papers), PARP inhibition in cancer therapy (23 papers), Testicular diseases and treatments (15 papers) and Genital Health and Disease (13 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (33.7k citations), Oncology (13.0k citations), Cancer Research (4.9k citations), Molecular Biology (5.9k citations) and Geriatrics and Gerontology (273 citations). Fred Saad has collaborated with scholars based in Canada, United States and Germany. Frequent co-authors include Karim S. Fizazi, Neal D. Shore, Pierre I. Karakiewicz, Johann Sebastian De Bono, Cora Nanette Sternberg, Kim N. Chi, Allan Lipton, Paul N. Mainwaring, Shahrokh François Shariat and Anne‐Marie Mes‐Masson. Their work appears in journals such as Annals of Oncology, The Journal of Urology, European Urology, Urologic Oncology Seminars and Original Investigations and Clinical Genitourinary Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.